Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate
Public ClinicalTrials.gov record NCT00101816. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of BMS-354825 in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to see what effect an investigational drug (BMS-354825) has on subjects who are currently in the myeloid blast phase of chronic myeloid leukemia (CML) and who are either resistant to or intolerant of imatinib mesylate. Another purpose of the study is to see what side effects this drug may have on subjects.
Study identification
- NCT ID
- NCT00101816
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 124 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2004
- Primary completion
- Jul 31, 2006
- Completion
- Feb 29, 2008
- Last update posted
- Aug 9, 2010
2004 – 2008
United States locations
- U.S. sites
- 23
- U.S. states
- 18
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution | Birmingham | Alabama | — | — |
| Local Institution | Anaheim | California | — | — |
| Local Institution | Los Angeles | California | — | — |
| Local Institution | Stanford | California | — | — |
| Local Institution | Vallejo | California | — | — |
| Local Institution | Denver | Colorado | — | — |
| Local Institution | Jacksonville | Florida | — | — |
| Local Institution | Tampa | Florida | — | — |
| Local Institution | Atlanta | Georgia | — | — |
| Local Institution | Chicago | Illinois | — | — |
| Local Institution | Kansas City | Kansas | — | — |
| Local Institution | Baltimore | Maryland | — | — |
| Local Institution | Boston | Massachusetts | — | — |
| Local Institution | Detroit | Michigan | — | — |
| Local Institution | St Louis | Missouri | — | — |
| Local Institution | Hackensack | New Jersey | — | — |
| Local Institution | New Brunswick | New Jersey | — | — |
| Local Institution | New York | New York | — | — |
| Local Institution | Portland | Oregon | — | — |
| Local Institution | Pittsburgh | Pennsylvania | — | — |
| Local Institution | Nashville | Tennessee | — | — |
| Local Institution | Houston | Texas | — | — |
| Local Institution | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00101816, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 9, 2010 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00101816 live on ClinicalTrials.gov.